2025-06-29-PitchBook-PitchBook年一季度医疗科技VC和PE趋势（英）_10页_11mb

Summary of Q1 2025 Medtech VC and PE Trends

Q1 2025 showed strong momentum in medical technology (medtech) venture capital (VC) and private equity (PE) investment. VC activity reached $4.1 billion in funding, the highest since Q1 2022, with 216 confirmed transactions, reversing a four-quarter decline and significantly outpacing 2024's pace. Key investments included Neuralink's $650 million deal and Neko Health's $260 million Series B. In contrast, PE activity, with 44 deals, indicated early strength, drawing involvement from firms like TPG and Redmile Group, but exits remained scarce due to regulatory headwinds.

The medtech landscape spans remote monitoring, diagnostics, surgical devices, nonsurgical treatments, and medical imaging. Notable trends include convergence with digital health, exemplified by smart wearable adoption, and growth in whole-body imaging technologies. Exit opportunities are limited, with no major VC exits in Q1; however, three acquisitions and one public listing occurred, including Beta Bionics' IPO. Regulatory uncertainty, such as the FDA's decision on lab-developed tests and potential Medicaid cuts, poses challenges for long-term investments and capital planning.

Overall, 2025 is shaping up as a robust year for medtech funding, with VC dominating deal-making and PE showing potential for exits. Future outlook highlights increasing PE-backed IPOs, like Caris Life Sciences, amid broader healthcare M&A trends. The convergence of medtech and digital health may drive further opportunities, but regulatory risks persist.